KLRK1 and neoplasm: The evidence as a whole suggests that upregulation of NKG2D ligands on early stage tumor cells is part of a host defense mechanism, but that the immune response subsequently applies selective pressure for tumors that have either extinguished expression of NKG2D ligands or have activated immune suppressive mechanisms (Raulet and Guerra, 2009).